El Nekidy, W.S.; Al Ali, M.; Abidi, E.; El Lababidi, R.; Alrahmany, D.; Ghazi, I.M.; Mooty, M.; Hijazi, F.; Ghosn, M.; Mallat, J.
Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy. Antibiotics 2024, 13, 699.
https://doi.org/10.3390/antibiotics13080699
AMA Style
El Nekidy WS, Al Ali M, Abidi E, El Lababidi R, Alrahmany D, Ghazi IM, Mooty M, Hijazi F, Ghosn M, Mallat J.
Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy. Antibiotics. 2024; 13(8):699.
https://doi.org/10.3390/antibiotics13080699
Chicago/Turabian Style
El Nekidy, Wasim S., Mooza Al Ali, Emna Abidi, Rania El Lababidi, Diaa Alrahmany, Islam M. Ghazi, Mohamad Mooty, Fadi Hijazi, Muriel Ghosn, and Jihad Mallat.
2024. "Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy" Antibiotics 13, no. 8: 699.
https://doi.org/10.3390/antibiotics13080699
APA Style
El Nekidy, W. S., Al Ali, M., Abidi, E., El Lababidi, R., Alrahmany, D., Ghazi, I. M., Mooty, M., Hijazi, F., Ghosn, M., & Mallat, J.
(2024). Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy. Antibiotics, 13(8), 699.
https://doi.org/10.3390/antibiotics13080699
